plicamycin has been researched along with Neurodegenerative Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, X; Huang, Q; Li, M; Ma, S; Xu, S; Yu, Q | 1 |
| Chatterjee, S; Conforto, A; Ratan, RR; Ryu, H; Zaman, K | 1 |
2 other study(ies) available for plicamycin and Neurodegenerative Diseases
| Article | Year |
|---|---|
Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson's disease.
Topics: Animals; Astrocytes; Calcium-Binding Proteins; CD11b Antigen; Cytokines; Disease Models, Animal; Dopamine; Early Growth Response Protein 1; Enzyme Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Microfilament Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Phosphopyruvate Hydratase; Plicamycin; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2018 |
Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons.
Topics: Animals; Apoptosis; Base Sequence; Brain; Cell Culture Techniques; Chromomycin A3; DNA Damage; Electrophoresis; Microscopy, Phase-Contrast; Neurodegenerative Diseases; Neurons; Oxidative Stress; Plicamycin; Rats; Rats, Sprague-Dawley | 2001 |